Table 5.
The top 10 co-cited references related to CAR-NK cells. .
| Top 10 co-cited references (only including articles) related to CAR-NK cells | ||||||
|---|---|---|---|---|---|---|
| Rank | Year | Author | Title | Journal | Co-citation | Centrality |
| 1 | 2020 | Liu EL et al. (16) | Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors | N Engl J Med | 214 | 0.01 |
| 2 | 2018 | Liu EL et al. (26) | Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity | Leukemia | 173 | 0.04 |
| 3 | 2018 | Li Y et al. (27) | Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity | Cell Stem Cell | 153 | 0.01 |
| 4 | 2018 | Tang XW et al. (28) | First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia | Am J Cancer Res | 112 | 0.01 |
| 5 | 2017 | Zhang CC et al. (20) | Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity | Front Immunol | 87 | 0.01 |
| 6 | 2015 | Schönfeld K et al. (29) | Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor | Mol Ther | 86 | 0.01 |
| 7 | 2014 | Chu J et al. (30) | CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma | Leukemia | 83 | 0.02 |
| 8 | 2016 | Romanski A et al. (31) | CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies | J Cell Mol Med | 70 | 0.01 |
| 9 | 2015 | Zhang CC et al. (32) | ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma | J Natl Cancer Inst | 64 | 0.01 |
| 10 | 2017 | Oelsner S et al. (33) | Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma | Cytotherapy | 63 | 0 |
| Top 10 co-cited references (only including reviews) related to CAR-NK cells | ||||||
| 1 | 2017 | Rezvani K et al. (34) | Engineering Natural Killer Cells for Cancer Immunotherapy | Mol Ther | 89 | 0 |
| 2 | 2016 | Suck G et al. (35) | NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy | Cancer Immunol Immunother | 84 | 0.01 |
| 3 | 2016 | Klingemann H et al. (36) | Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells | Front Immunol | 80 | 0 |
| 4 | 2018 | Mehta RS et al. (37) | Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer | Front Immunol | 75 | 0 |
| 5 | 2015 | Glienke W et al. (38) | Advantages and applications of CAR-expressing natural killer cells | Front Pharmacol | 63 | 0.01 |
| 6 | 2020 | Xie GZ et al. (39) | CAR-NK cells: A promising cellular immunotherapy for cancer | EBioMedicine | 33 | 0 |
| 7 | 2016 | Guillerey C et al. (40) | Targeting natural killer cells in cancer immunotherapy | Nat Immunol | 49 | 0 |
| 8 | 2018 | Hu Y et al. (41) | Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy | Acta Pharmacol Sin | 49 | 0 |
| 9 | 2019 | Hu WL et al. (42) | Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities | Front Immunol | 35 | 0 |
| 10 | 2015 | Rezvani K et al. (43) | The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer | Front Immunol | 29 | 0 |